Chinook Therapeutics, Inc.
(NASDAQ : ADRO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.17%170.820.7%$967.58m
ABBVAbbVie, Inc. 1.33%139.881.9%$839.03m
PFEPfizer Inc. 0.32%49.430.9%$827.77m
LLYEli Lilly & Co. -0.23%300.631.1%$744.48m
MRKMerck & Co., Inc. 0.21%87.590.7%$741.41m
BMYBristol-Myers Squibb Co. 0.68%72.611.0%$654.24m
SIGASIGA Technologies, Inc. -4.94%22.150.0%$392.48m
AZNAstraZeneca Plc -0.59%65.641.0%$379.22m
ALNYAlnylam Pharmaceuticals, Inc. 4.76%228.998.1%$252.76m
GSKGSK Plc -0.20%40.490.3%$217.43m
HZNPHorizon Therapeutics Plc 1.48%70.635.4%$200.72m
SGENSeagen Inc. 2.06%179.435.7%$192.63m
NVSNovartis AG 0.69%86.160.2%$174.58m
RGENRepligen Corp. 0.77%248.176.7%$156.95m
NVONovo Nordisk A/S -0.29%102.900.1%$152.45m

Company Profile

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.